KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Cash from Operations (2016 - 2025)

Sarepta Therapeutics (SRPT) has 15 years of Cash from Operations data on record, last reported at 131206000.0 in Q4 2025.

  • For Q4 2025, Cash from Operations rose 42.54% year-over-year to 131206000.0; the TTM value through Dec 2025 reached 205479000.0, changed 0.15%, while the annual FY2025 figure was 205479000.0, 0.15% changed from the prior year.
  • Cash from Operations reached 131206000.0 in Q4 2025 per SRPT's latest filing, up from 14585000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 261337000.0 in Q2 2025 and bottomed at 583437000.0 in Q1 2025.
  • Average Cash from Operations over 5 years is 84038850.0, with a median of 81545500.0 recorded in 2022.
  • Peak YoY movement for Cash from Operations: plummeted 215.05% in 2022, then soared 1649.01% in 2025.
  • A 5-year view of Cash from Operations shows it stood at 29326000.0 in 2021, then tumbled by 215.05% to 92392000.0 in 2022, then surged by 40.84% to 54657000.0 in 2023, then skyrocketed by 268.41% to 92046000.0 in 2024, then soared by 42.54% to 131206000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Operations were 131206000.0 in Q4 2025, 14585000.0 in Q3 2025, and 261337000.0 in Q2 2025.